FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023160675> ?p ?o ?g. }

• W2023160675 endingPage "116" @default.
• W2023160675 startingPage "112" @default.
• W2023160675 abstract "To report on the first multicenter Italian experience with zonisamide as an add-on drug for refractory generalised or partial epilepsy in children, adolescents and young adults.The patients were enrolled in a prospective, add-on, open-label treatment study from eight Italian centres for children and adolescent epilepsy care. Eighty-two young patients (45 males, 37 females), aged between 3 and 34 years (mean 13.1 years), all affected by partial (47) or generalised (35) refractory epilepsy, were enrolled in the study. ZNS was added to the baseline therapy at a starting dose of 1 mg/kg/day twice daily. This dose was increased by 2 mg/kg every 1-2 weeks over a period of up 3 months, according to the patient's response and tolerability, up to a maximum dose of 12 mg/kg. ZNS was given at the mean daily dose of 5.7/mg/kg/24 h (range 1-12 mg/kg).After a mean follow-up period of 11.9 months (range 2-64 months), 9 patients (10.9%) were seizure-free. The number of seizures decreased by 50-99% in 31 cases (37.8%), by 25-49% in 5 cases (6.1%), remained the same in 29 cases (35.4%) and increased in 8 cases (9.7%). After 15 months of follow-up, 61 patients (74.4%) were still taking ZNS, while the remaining 21 (25.6%) had stopped. Twenty-two patients (26.8%) reported adverse effects while taking ZNS. They generally appeared during the first weeks of treatment, and were mild to moderate. The most frequent adverse effects were irritability and a reduced appetite.ZNS effectively reduced seizure frequency in this pediatric population with both partial and generalised crypto/symptomatic refractory epilepsy. Its overall tolerability was good." @default.
• W2023160675 created "2016-06-24" @default.
• W2023160675 creator A5007451076 @default.
• W2023160675 creator A5013585220 @default.
• W2023160675 creator A5017782497 @default.
• W2023160675 creator A5021199798 @default.
• W2023160675 creator A5022190213 @default.
• W2023160675 creator A5033179657 @default.
• W2023160675 creator A5067012061 @default.
• W2023160675 creator A5073113713 @default.
• W2023160675 creator A5074767492 @default.
• W2023160675 creator A5075424453 @default.
• W2023160675 creator A5077685439 @default.
• W2023160675 creator A5080828723 @default.
• W2023160675 creator A5082103373 @default.
• W2023160675 date "2009-02-01" @default.
• W2023160675 modified "2023-09-27" @default.
• W2023160675 title "Zonisamide in children and young adults with refractory epilepsy: An open label, multicenter Italian study" @default.
• W2023160675 cites W1571482608 @default.
• W2023160675 cites W1594127475 @default.
• W2023160675 cites W1976583040 @default.
• W2023160675 cites W2006257538 @default.
• W2023160675 cites W2040265255 @default.
• W2023160675 cites W2066411741 @default.
• W2023160675 cites W2089167434 @default.
• W2023160675 cites W2093234431 @default.
• W2023160675 cites W2094073112 @default.
• W2023160675 cites W2116350989 @default.
• W2023160675 cites W2147656366 @default.
• W2023160675 cites W4236676256 @default.
• W2023160675 doi "https://doi.org/10.1016/j.eplepsyres.2008.10.012" @default.
• W2023160675 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19081227" @default.
• W2023160675 hasPublicationYear "2009" @default.
• W2023160675 type Work @default.
• W2023160675 sameAs 2023160675 @default.
• W2023160675 citedByCount "25" @default.
• W2023160675 countsByYear W20231606752012 @default.
• W2023160675 countsByYear W20231606752013 @default.
• W2023160675 countsByYear W20231606752014 @default.
• W2023160675 countsByYear W20231606752015 @default.
• W2023160675 countsByYear W20231606752016 @default.
• W2023160675 countsByYear W20231606752017 @default.
• W2023160675 countsByYear W20231606752018 @default.
• W2023160675 countsByYear W20231606752019 @default.
• W2023160675 countsByYear W20231606752021 @default.
• W2023160675 countsByYear W20231606752022 @default.
• W2023160675 crossrefType "journal-article" @default.
• W2023160675 hasAuthorship W2023160675A5007451076 @default.
• W2023160675 hasAuthorship W2023160675A5013585220 @default.
• W2023160675 hasAuthorship W2023160675A5017782497 @default.
• W2023160675 hasAuthorship W2023160675A5021199798 @default.
• W2023160675 hasAuthorship W2023160675A5022190213 @default.
• W2023160675 hasAuthorship W2023160675A5033179657 @default.
• W2023160675 hasAuthorship W2023160675A5067012061 @default.
• W2023160675 hasAuthorship W2023160675A5073113713 @default.
• W2023160675 hasAuthorship W2023160675A5074767492 @default.
• W2023160675 hasAuthorship W2023160675A5075424453 @default.
• W2023160675 hasAuthorship W2023160675A5077685439 @default.
• W2023160675 hasAuthorship W2023160675A5080828723 @default.
• W2023160675 hasAuthorship W2023160675A5082103373 @default.
• W2023160675 hasBestOaLocation W20231606752 @default.
• W2023160675 hasConcept C118552586 @default.
• W2023160675 hasConcept C121332964 @default.
• W2023160675 hasConcept C126322002 @default.
• W2023160675 hasConcept C141071460 @default.
• W2023160675 hasConcept C142424586 @default.
• W2023160675 hasConcept C187212893 @default.
• W2023160675 hasConcept C188816634 @default.
• W2023160675 hasConcept C197934379 @default.
• W2023160675 hasConcept C205545832 @default.
• W2023160675 hasConcept C2777138316 @default.
• W2023160675 hasConcept C2777683783 @default.
• W2023160675 hasConcept C2778186239 @default.
• W2023160675 hasConcept C2778375690 @default.
• W2023160675 hasConcept C3019985608 @default.
• W2023160675 hasConcept C42219234 @default.
• W2023160675 hasConcept C71924100 @default.
• W2023160675 hasConcept C87355193 @default.
• W2023160675 hasConceptScore W2023160675C118552586 @default.
• W2023160675 hasConceptScore W2023160675C121332964 @default.
• W2023160675 hasConceptScore W2023160675C126322002 @default.
• W2023160675 hasConceptScore W2023160675C141071460 @default.
• W2023160675 hasConceptScore W2023160675C142424586 @default.
• W2023160675 hasConceptScore W2023160675C187212893 @default.
• W2023160675 hasConceptScore W2023160675C188816634 @default.
• W2023160675 hasConceptScore W2023160675C197934379 @default.
• W2023160675 hasConceptScore W2023160675C205545832 @default.
• W2023160675 hasConceptScore W2023160675C2777138316 @default.
• W2023160675 hasConceptScore W2023160675C2777683783 @default.
• W2023160675 hasConceptScore W2023160675C2778186239 @default.
• W2023160675 hasConceptScore W2023160675C2778375690 @default.
• W2023160675 hasConceptScore W2023160675C3019985608 @default.
• W2023160675 hasConceptScore W2023160675C42219234 @default.
• W2023160675 hasConceptScore W2023160675C71924100 @default.
• W2023160675 hasConceptScore W2023160675C87355193 @default.
• W2023160675 hasIssue "2-3" @default.
• W2023160675 hasLocation W20231606751 @default.
• W2023160675 hasLocation W20231606752 @default.

• next